CAS 1325559-30-5|FlufenaMic acid-13C6
| Common Name | FlufenaMic acid-13C6 | ||
|---|---|---|---|
| CAS Number | 1325559-30-5 | Molecular Weight | 287.186 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C813C6H10F3NO2 | Melting Point | / |
| MSDS | USA | Flash Point | / |
| Symbol | GHS05 | Signal Word | Danger |
Names
| Name | FlufenaMic acid-13C6 |
|---|---|
| Synonym | More Synonyms |
FlufenaMic acid-13C6 BiologicalActivity
| Description | Flufenamic acid-13C6 is the 13C6 labeled Flufenamic acid. Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca2+ channels, modulating non-selective cation channels (NSC), activating K+ channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation. |
|---|---|
| Related Catalog | Signaling Pathways >>Membrane Transporter/Ion Channel >>Calcium ChannelSignaling Pathways >>Epigenetics >>AMPKSignaling Pathways >>Membrane Transporter/Ion Channel >>Chloride ChannelResearch Areas >>Inflammation/ImmunologySignaling Pathways >>Immunology/Inflammation >>COXSignaling Pathways >>PI3K/Akt/mTOR >>AMPKSignaling Pathways >>Membrane Transporter/Ion Channel >>Potassium Channel |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| References | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [2]. Guinamard R, et al. Flufenamic acid as an ion channel modulator. Pharmacol Ther. 2013 May;138(2):272-84. [3]. Pongkorpsakol P, et al. Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation. Eur J Pharmacol. 2017 Mar 5;798:94-104. [4]. Pongkorpsakol P, et al. Cellular mechanisms underlying the inhibitory effect of flufenamic acid on chloride secretion in human intestinal epithelial cells. J Pharmacol Sci. 2017 Jun;134(2):93-100. [5]. Pobbati AV, et al. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Structure. 2015;23(11):2076-2086. |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C813C6H10F3NO2 |
| Molecular Weight | 287.186 |
| Exact Mass | 287.086487 |
| Index of Refraction | 1.585 |
Safety Information
| Symbol | GHS05 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H315-H318 |
| Precautionary Statements | P280-P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Phrases | 38-41 |
| Safety Phrases | 26-39 |
| RIDADR | NONH for all modes of transport |
Synonyms
| 2-{[3-(Trifluoromethyl)phenyl]amino}(13C6)benzoic acid |
| MFCD20036276 |
| Flufenamic acid-(benzoic ring-13C6) |
| 2-(3-Trifluoromethylphenylamino)benzoic-13C6 acid |
| Benzoic-1,2,3,4,5,6-13C6 acid, 2-[[3-(trifluoromethyl)phenyl]amino]- |
